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Abstract: 
 
Scope: Lipotoxicity‐induced endothelial dysfunction is an important vascular complication 
associated with diabetes. Clinical studies support the vascular benefits of blueberry 
anthocyanins, but the underlying mechanism is unclear. The hypothesis that metabolites of 
blueberry anthocyanins attenuate lipotoxicity‐induced endothelial dysfunction was tested. 
Methods and results: Human aortic endothelial cells (HAECs) were treated for 6 h with either: 
(i) the parent anthocyanins (malvidin‐3‐glucoside and cyanidin‐3‐glucoside); or (ii) the blueberry 
metabolites (hydroxyhippuric acid, hippuric acid, benzoic acid‐4‐sulfate, isovanillic acid‐3‐
sulfate, and vanillic acid‐4‐sulfate), at concentrations known to circulate in humans following 
blueberry consumption. For the last 5 h HAECs were treated with palmitate or vehicle. HAECs 
treated with palmitate displayed elevated reactive oxygen species generation, increased mRNA 
expression of NOX4, chemokines, adhesion molecules, and IκBα, exaggerated monocyte 
binding, and suppressed nitric oxide production. Of note, the damaging effects of palmitate were 
ameliorated in HAECs treated with blueberry metabolites but not parent anthocyanins. Further, 
important translational relevance of these results was provided by our observation that palmitate‐
induced endothelial dysfunction was lessened in arterial segments that incubated concurrently 
with blueberry metabolites. Conclusion: The presented findings indicate that the vascular 
benefits of blueberry anthocyanins are mediated by their metabolites. Blueberries might 
complement existing therapies to lessen vascular complications. 
 
Keywords: blueberry metabolites | endothelial dysfunction | inflammation | nitric oxide | 
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Article: 
 
1 Introduction 
 
Endothelial dysfunction is a characteristic phenotype of cardiovascular complications associated 
with diabetes and related metabolic disorders.1-3 Factors such as oxidative stress, hyperglycemia, 
lipotoxicity, and increased pro‐inflammatory cytokines are characteristic systemic disturbances 
in patients with insulin‐resistant conditions.1-5 Each component has potential to contribute 
independently and synergistically to endothelial dysfunction by increasing endothelial 
inflammation and decreasing endothelial cell nitric oxide (NO) bioavailability.3-5 This issue is 
clinically relevant because endothelial dysfunction contributes to pathological processes specific 
to large (atherosclerosis) and small (retinopathy, nephropathy, neuropathy) blood vessels.3, 6, 7 
Treating cardiovascular complications associated with insulin‐resistant conditions contributes to 
increasing medical costs that burden the patient and society. Hence, there is a need to elucidate 
effective, low‐cost, adjunct strategies to traditional therapies for treating vascular disease. 
 
Evidence from clinical and pre‐clinical models supports the vascular benefits of anthocyanins, 
one class of flavonoids widely available in berries.8-12 Anthocyanins are glycosides which are 
comprised of the anthocyanidin aglycone and a sugar moiety. Blueberries are an excellent source 
of anthocyanins that include galactosides, glucosides, and arabinosides of cyanidin, delphinidin, 
malvidin, peonidin, and petunidin.13 Recent studies showed that consumption of blueberries 
improves endothelial function in subjects with metabolic syndrome, reduces blood pressure in 
postmenopausal women with hypertension, and increases flow‐mediated dilation in healthy 
individuals.14-17 However, the mechanisms responsible for the vascular benefits of blueberry 
anthocyanins are unknown. 
 
Anthocyanins are quickly metabolized by digestive enzymes and intestinal microbiota in humans 
suggesting vasculoprotection might be mediated by their circulating metabolites.14 The role of 
blueberry metabolites in contributing to or being responsible for the vascular benefits of 
blueberry consumption has not been studied in a comprehensive manner because several of these 
compounds are not commercially available.18 We addressed this issue by synthesizing the key 
blueberry metabolites and tested the hypothesis that lipotoxicity‐induced endothelial dysfunction 
is lessened by blueberry metabolites. 
 
2 Experimental Section 
 
2.1 Materials 
 
Human aortic endothelial cells (HAECs), endothelial basal medium‐2 (EBM‐2), and EGM‐2 
SingleQuot kit supplements and growth factors were purchased from Lonza (Allendale, NJ). 
Fetal bovine serum (FBS), cell culture supplements, calcein‐AM, and RPMI 1640 were from 
Invitrogen (Carlsbad, CA); cell titer blue from Promega (Madison, WI); protein assay kits were 
from Bio‐Rad (Hercules, CA); fatty acid‐free BSA from Fisher Scientific (Hampton, NH); 
palmitate, protease and phosphatase inhibitor cocktails, malvidin‐3‐glucoside, cyanidin‐3‐
glucoside, hippuric acid, hydroxyhippuric acid, 4‐amino‐5‐methylamino‐2′,7′‐difluorofluorescein 
diacetate (DAF), 2′,7′‐dichlorofluorescein diacetate, and other general chemicals were obtained 
from Sigma–Aldrich (St. Louis, MO). Human monocytic THP1 cells were from American Type 
Culture Collection (Manassas, VA). RNeasy plus mini kit, QuantiTech reverse transcription kit, 
SYBR qPCR (quantitative PCR) green master mix, and primers were purchased from Qiagen 
(Valencia, CA). 
 
2.2 Synthesis of Blueberry Metabolites 
 
The blueberry metabolites benzoic acid‐4‐sulfate (BAS; compound 3a), isovanillic acid‐3‐sulfate 
(IVAS; compound 3b), vanillic acid‐4‐sulfate (VAS; compound 3c) were generated using a 
three‐step protocol (Figure 1A) that was modified from a previously published procedure.18 
Starting with 4‐hydroxybenzoic acid (1a), isovanillic acid (IVA) (1b), or vanillic acid (1c), 
selective protection of carboxylic acid with cesium carbonate and benzyl bromide provided the 
benzyl esters. Installation of the protected sulfate was accomplished with the use of the 2,2,2‐
trichloroethyl sulfurochloridate Cl3CCH2OSO2Cl (TCE) group19, 20 to afford the sulfonylated 
intermediates 2a–c. Although a deprotection step is required, utilization of TCE is a reliable 
method for sulfonylation of phenolic groups.21 Compounds (3a–c) were obtained as the 
ammonium salts by using atmospheric pressure H2(g) and stirring overnight in the presence of 
ammonium formate. The purity of each compound was verified by NMR (Supporting 
Information Figure S1A–C). The locally synthesized compounds VAS, IVAS, and BAS 
(Figure 1B) were combined with commercially available blueberry metabolites hydroxy hippuric 
acid (HHA) and hippuric acid (HA), and their combination is referred to as the blueberry 
metabolite mixture. 
 
 
Figure 1. A) Three step protocol utilized to synthesize benzoic acid 4‐sulfate (3a), isovanillic acid 3‐sulfate (3b), 
and vanillic acid 4‐sulfate (3c). Starting material: 4‐hydroxy benzoic acid (1a), isovanillic acid (1b), and vanillic 
acid (1c). B) Structures of benzoic acid 4‐sulfate, isovanillic acid 3‐sulfate, and vanillic acid 4‐sulfate. 
 
2.3 In Vitro Analyses of Cellular Function 
 
2.3.1 Cell Culture 
 
HAECs were cultured in EBM‐2 supplemented with EGM‐2 SingleQuot endothelial growth 
supplements (Lonza, MD) and 2% heat inactivated FBS at 37 °C in a 5% CO2/95% oxygen 
environment. HAECs were passaged at 70–80% confluency and studied at passages 5–
7.22, 23 Human monocytic THP1 cells (American Type Culture Collection, VA) were cultured in 
RPMI‐1640 medium with 10% FBS.23 
 
2.3.2 Palmitate, Blueberry Metabolites, and Parent Anthocyanins Treatment 
 
HAECs were treated for 6 h with either: (i) parent anthocyanins (16 nm malvidin‐3‐glucoside 
and 12 nm cyanidin‐3‐glucoside); (ii) blueberry metabolites mixture (75 nm VAS, 75 nm IVAS, 
700 nm BAS, 3 μm HHA, and 5 μM HA); (iii) individual metabolites; or (iv) the solubilizing 
vehicle DMSO. For the last 5 h HAECs in each condition were treated with 500 μm palmitate or 
the vehicle [bovine serum albumin (BSA)]. Palmitate (C16:0) (Sigma, MO) was coupled to fatty 
acid‐free BSA (Fisher Scientific, NH) in the ratio of 2 m palmitate to 1 m BSA (palmitate‐
BSA).24-26 The dose of palmitate was chosen based on earlier studies indicating its ability to 
evoke a lipotoxic stress in cells and arteries without causing cell death or apoptosis.24-26 Further, 
studies indicate that palmitate is a predominant circulating saturated free fatty acid, and 500 μm 
palmitate mimics circulating pathophysiological conditions.25 Upon completing the respective 
treatments, the following end‐points were assessed in HAECs: monocyte binding; mRNA 
expression of NOX4, chemokines, and adhesion molecules; indices of nuclear factor kB (NFκB) 
signaling; and estimates of reactive oxygen species (ROS) and NO production. 
 
2.3.3 Rationale for the Concentration of Parent Anthocyanins and Blueberry Metabolites 
 
Evidence shows that less than 2% of parent anthocyanin reaches the circulation or target organs 
following the consumption of berries.13, 27 A recent study showed that only three anthocyanins 
(malvidin‐3‐glucoside, cyanidin‐3‐glucoside, and delphinidin‐3‐glucoside) appear in the plasma 
of humans following the consumption of blueberry puree which contains 12 anthocyanins.28 
Further, in this study delphinidin‐3‐glucoside was not detected in the plasma of all volunteers. 
Based on this study we used two parent anthocyanins (16 nm malvidin‐3‐glucoside and 12 nm 
cyanidin‐3‐glucoside) in our experiment. This dosage represents the concentration of these 
parent anthocyanins detected in the plasma following consumption of 300 g of blueberry puree.28 
 
Anthocyanins are extensively metabolized by phase II enzymes and intestinal microbiota leading 
to the formation of diverse phenolic metabolites.14 Indeed, 61 phenolic metabolites appear in the 
plasma following the consumption of blueberry.13 However, only selected metabolites may be 
responsible for the specific biological effects of blueberry. A recent study measured the 
blueberry metabolites circulating in plasma at the time of the observed biological effect.16 Intake 
of anthocyanins that is equivalent to ≈240 g ( ≈2 cups) of blueberries increased flow‐mediated 
dilation in humans that was accompanied by increases in the plasma concentrations of phenolic 
metabolites such as VA, homovanillic acid, benzoic acid, HA, and HHA.16 This suggests that 
these metabolites may be responsible for the improvements in endothelial function. In this study, 
samples were prepared by using enzymatic hydrolysis with sulfatase to produce non‐sulfated 
metabolites for plasma metabolite analysis. Human studies reported that some of these 
metabolites exist as sulfated metabolites such as VAS, IVAS, and BAS in the plasma of 
humans.29, 30 Based on these human studies, a physiologically relevant mixture of blueberry 
metabolites was calculated i.e., 75 nm VAS, 75 nm IVAS, 700 nm BAS, 3 μm HHA, and 5 
μm HA. This mixture/dosage closely represents the circulating levels of these metabolites in 
humans that consume ≈ 240 g of blueberries. Collectively, the choice and dosages of parent 
anthocyanins and metabolites used in our study are based on available published evidence, and 
physiologically relevant concentrations that have been reported. 
 
Stock solution of 20 000 × blueberry metabolites mixture or parent anthocyanins in DMSO was 
prepared and stored at −80 °C before use. 
 
2.3.4 Cell Viability Assessment 
 
We measured the effect of palmitate and/or blueberry metabolites on cell viability. Cell viability 
following palmitate or metabolites treatment was estimated as [(number of cells per field before 
treatment − number of cells per field after treatment) / (number of cells per field before 
treatment)] × 100.24-26, 31, 32 Cell viability was also assessed using cell titer blue based on 
manufacturer's instruction. 
 
2.3.5 Monocyte Adhesion Assay 
 
Monocyte adhesion was determined using fluorescent‐labelled THP‐1 human monocytic cells as 
we described.23 Tumor necrosis factor‐α (TNF‐α) was used as a positive control and HAEC were 
incubated with 10 μg L−1 TNF‐α for 6 h before adhesion assay. 
 
2.3.6 Gene Expression Analysis by Quantitative Real‐Time PCR 
 
Gene expression analysis of IL‐8, monocyte chemotactic protein‐1 (MCP‐1), vascular adhesion 
molecule‐1 (VCAM‐1), intercellular adhesion molecule‐1 (ICAM‐1), NFκB ‐ p65, inhibitor κB 
kinase (IκKβ), IκBα, and NADPH oxidase 4 (NOX4) was determined by qPCR as described.33 
Briefly, mRNA was isolated from HAECs using the RNeasy plus mini kit and cDNA was 
synthesized using the reverse transcription kit.33 qPCR analysis was completed with cDNA 
template, SYBR Green Master Mix, and the respective Qiagen primer sets for IL‐8, MCP‐1, 
VCAM‐1, ICAM‐1, IκKβ, IκBα, and NOX4. The obtained signal was analyzed in Applied 
Biosystems QuantStudio 12K Flex Real‐Time PCR System (Thermo Fisher Scientific). Copy 
numbers of cDNA targets were quantified using Ct values. Respective gene expression levels 
were calculated by normalizing to the level of the housekeeping gene GAPDH.32 
 
2.3.7 ROS and NO Assay 
 
Estimates of ROS and NO production were made using 2′,7′‐dichlorofluorescein diacetate and 4‐
amino‐5‐methylamino‐2′,7′‐difluorofluorescein diacetate (diaminofluorescein diacetate; DAF‐
FM diacetate) (Sigma), respectively, as we described.31 To determine insulin‐stimulated NO 
production HAECs were treated with 100 nm insulin for the last 30 min of each respective 
treatment as we described.24-26, 31, 32 
 
2.4 Ex Vivo Analyses of Vascular Function 
 
2.4.1 Animals 
 
Seven‐week old male C57Bl/6J mice were obtained from the Jackson Laboratories, USA. 
Animals were housed under controlled temperature and light conditions and were provided with 
food and water ad libitum. C57BL/6 male mice are a widely used animal model to study vascular 
function and we have previously used these mice for ex vivo vessel function experiments.24-26 
We used segments of aortae from male mice for ex vivo vessel experiments due to concerns that 
ovary‐intact female animals are intrinsically more variable than males because of cyclical 
reproductive hormones.34 Mice live to be ≈ 24 months and our model would be equivalent to a 
young‐adult i.e., 20 years of age. We used eight segments of aortae per group for the vessel 
function experiment. The major difference in outcome was expected between BSA vs Pal and 
Pal vs Pal + blueberry metabolite treated vessels. The sample size was based on a previous study 
that determined vessel function in BSA vs palmitate treated vessel.35 With a comparable effect 
size, we estimated that the sample size of eight will provide 80% power (estimated by f‐test, 
analysis of variance (ANOVA), alpha = 0.05). All experiments were performed in accordance 
with protocols approved by the Institutional Animal Care and Use Committee at the University 
of Utah (Protocol number: 15–12011). 
 
2.4.2 Tissue Preparation and Measurement of Vascular Function 
 
Mice were anesthetized using 2–5% isoflurane. When an adequate plane of anesthesia was 
achieved, the chest was opened, the heart excised, and the entire aorta was isolated while 
immersed in ice‐cold normal physiological saline solution, and removed from the chest. The 
aortic segments isolated from male C57Bl/6J mice (7.1 ± 0.3 weeks of age; 25.8 ± 0.8 g body 
weight) were cut into equal segments that were incubated for 16 h with BSA, 500 μm palmitate + 
DMSO, or 500 μm palmitate + blueberry metabolites. After each treatment segments were used 
to assess vascular function (Supporting Information Table) using isometric tension techniques as 
we described.24-26 
 
2.5 Data Analyses 
 
Data are presented as mean ± SE, and p < 0.05 was considered significantly different. 
Comparison of one time point among groups was made using one‐way ANOVA with SPSS/10. 
Comparison of multiple time points among groups was made using a one‐way or two‐way 
repeated‐measure ANOVA using Prism. Tukey post hoc tests were performed when significant 
main effects were obtained. 
 
3 Results and Discussion 
 
We tested the overall hypothesis that vascular benefits of blueberry anthocyanins reported to 
exist in clinical and preclinical models are mediated by their circulating metabolites. To this 
point, a comprehensive evaluation of this hypothesis has been difficult to explore because many 
of the metabolites are not available commercially. We addressed this issue by synthesizing three 
important blueberry metabolites (VAS, IVAS, and BAS) and combining them with two 
metabolites that do exist commercially (HHA and HA) to comprise a physiologically relevant 
blueberry metabolites mixture. The ability of blueberry metabolites to lessen lipotoxicity‐
induced endothelial dysfunction was assessed and compared to that exerted by the parent 
anthocyanins. 
 
3.1 Characterization of Blueberry Metabolites and Cell Viability 
 
The purity and identity of VAS, IVAS, and BAS were confirmed by NMR (Supplementary 
Figure 1A–C). Blueberry metabolites or palmitate treatment at the dosage and duration used in 
this study did not reduce cell viability (Supporting Information Figure S2A and B). 
 
3.2 Palmitate‐Induced Endothelial Inflammation is Prevented by Blueberry Metabolites but not 
by Parent Anthocyanins 
 
We tested whether palmitate‐induced adhesion and inflammation are attenuated by blueberry 
metabolites. As expected, palmitate increased the binding of monocytic THP1 cells to HAECs as 
compared to control (Figure 2A). In support of our hypothesis, palmitate‐induced monocyte 
binding to HAECs was prevented in HAECs treated with blueberry metabolites (Figure 2A). 
This is clinically relevant because exaggerated monocyte binding to the endothelium is a key 
initial event in the pathogenesis of endothelial dysfunction.14, 22, 36 In contrast, the parent 
anthocyanins failed to exert such a protective effect (Figure 2A). We further investigated the 
influence of individual metabolites at physiologically‐relevant concentrations on monocyte 
binding to ECs. BAS (p = 0.077) and HA (p = 0.054) modestly reduced palmitate‐induced 
monocyte binding to HAECs (Figure 2B). These data suggest beneficial vascular effects of 
blueberries could be secondary to the synergistic effect(s) of circulating metabolites. 
 
Next we examined whether the beneficial effect of blueberry metabolites on monocyte binding 
might result from their ability to limit palmitate‐induced activation of chemokines and adhesion 
molecules. Activation of chemokines and adhesion molecules is required for monocyte rolling, 
enhanced endothelium‐monocyte interaction, and subsequent monocyte recruitment into the 
subendothelial space.22, 23, 37 Palmitate increased the mRNA expression of IL8, MCP1, ICAM1, 
VCAM1, and E‐Selectin (Figure 2C and D), major inflammatory factors involved in endothelial 
dysfunction.22, 23 Blueberry metabolites completely prevented palmitate‐induced expression of 
IL‐8, ICAM1, and VCAM1 in HAECs (Figure 2C and D). Although treatment with the parent 
anthocyanins did not negate palmitate‐induced inflammation and adhesion, a modest attenuation 
of MCP1 activation was observed (Figure 2E and F). Thus, palmitate‐induced endothelial 
inflammation and adhesion is sensitive to treatment with blueberry metabolites but not their 
parent anthocyanins. 
 
 
Figure 2. HAECs treated ± parent anthocyanins (Ac) ± blueberry metabolites ± vehicle for 6 h and with or without 
palmitate‐BSA (Pal) or vehicle (BSA) for the last 5 h. A) The binding of monocyte to HAECs was determined by 
using fluorescent‐labelled THP‐1 human monocytic cells. TNF‐α (6 h × 10 μg L−1) served as a positive control. 
Values are mean ± SEM, n = 8 (means of triplicate). B) The binding of monocyte to HAECs was determined by 
using fluorescent labelled THP‐1 human monocytic cells. Values are mean ± SEM, n = 4 (means of triplicate). 
mRNA expression of IL‐8 and MCP1 C), and ICAM1, VCAM1 and E‐selectin D) were analyzed by qPCR using 
SYBR green. Values are mean ± SEM, n = 6 (means of duplicate). mRNA expression of IL‐8 and MCP1 E), and 
ICAM1, VCAM1 and E‐selectin F) and were analyzed by qPCR using SYBR green. Values are mean ± SEM, n = 4 
(means of duplicate). Means without a common letter differ, p < 0.05. 
 
3.3 Palmitate‐Induced Suppression of Insulin‐Stimulated NO Production is Prevented by 
Blueberry Metabolites 
 
Studies in cultured cells,26 isolated arteries,24-26, 38 animal models,24-26, 39 and humans40, 41 
demonstrate that lipotoxicity has strong potential to impair NO production. Endothelial cell 
derived NO has vasodilatory, anti‐inflammatory, and antiproliferative properties.3, 7, 14, 42 As 
such, any mismatch between production and destruction of this molecule has potential to 
precipitate cardiovascular complications. Therefore, we sought to determine whether blueberry 
metabolites might protect against the suppressed NO production that occurs in the context of 
lipotoxicity.24-26 Proof of concept for this hypothesis exists. For example, increased blood NO 
was reported in postmenopausal women with hypertension following blueberry consumption.15 
As predicted, palmitate reduced insulin‐stimulated NO production in HAECs, and this response 
was restored by concurrent treatment with blueberry metabolites (Figure 3A). 
 
 
Figure 3. HAECs were treated for 6 h with either: (i) Parent anthocyanins (Ac) [16 nM MG and 12 nM CG]; (ii) 
Blueberry metabolites [75 nm VAS, 75 nm IVAS, 700 nm BAS, 3 μm HHA, and 5 μm HA]; or (iii) the solubilizing 
vehicle DMSO. For the last 5 h HAECs in each condition were treated with 500 μM palmitate or the vehicle BSA. 
A) To determine insulin‐stimulated NO production HAEC were treated with 100 nm insulin (Ins) for the final 30 
min of each treatment. Values are mean ± SEM, n = 6 (means of duplicate). B) mRNA expression of endothelial 
nitric oxide synthase and NOX4 were analyzed by qPCR using SYBR green. Values are mean ± SEM, n = 4 (means 
of duplicate). C) ROS was determined by DCF assay. Values are mean ± SEM, n = 6 (means of duplicate). D) 
mRNA expression of NFκB‐p65, IκKβ and IκBα were analyzed by qPCR using SYBR green. Values are mean ± 
SEM, n = 4 (means of duplicate). Means without a common letter differ, p < 0.05. 
 
3.4 Palmitate‐Induced ROS Generation, NOX4 Expression, and IκBα Expression is Prevented by 
Blueberry Metabolites 
 
ROS play a major role in the development of endothelial dysfunction and NOX is an important 
source of ROS in the vasculature.7, 14 Palmitate can increase NOX levels in ECs that are 
associated with ROS production.43, 44 Congruent with this, we observed that palmitate increased 
NOX4 expression (Figure 3B) and ROS production (Figure 3C). As hypothesized, both effects 
were prevented by concurrent treatment with blueberry metabolites (Figure 3B and C). This 
finding suggests strongly that reduced NOX activity observed in healthy humans following 
blueberry intake16 might be mediated by their metabolites rather than by the parent anthocyanins. 
 
NFκB plays a major role in endothelial dysfunction by up‐regulating chemokines and adhesion 
molecules.2 Inhibitor κB kinase activates the nuclear translocation of NFκB‐p50/p65 by 
degrading the inhibitor IκBα.45 In the nucleus, p50/p65 binds to the promoters of NFκB‐
dependent inflammatory genes to thereby mediate endothelial dysfunction.46, 47 In the present 
study, the expression of NFκB‐p65 and IκKβ were refractory to palmitate‐treatment (Figure 3D). 
However, palmitate robustly increased the expression of IκBα and this effect was prevented by 
treatment with blueberry metabolites (Figure 3D). Although speculative, increased IκBα 
expression in palmitate‐treated HAECs might be an adaptive response to inhibit the nuclear 
translocation of p50/p65. Further, diminished IκBα expression after blueberry metabolite 
treatment could be secondary to a reduction of palmitate induced metabolic stress. 
 
3.5 Palmitate‐Induced Endothelium‐Dependent Dysfunction is Attenuated by Blueberry 
Metabolites 
 
We determined the extent to which our findings from HAECs might be translated to intact 
arteries. As hypothesized, the severity of palmitate‐induced endothelium‐dependent dysfunction 
was less in arteries treated with blueberry metabolites (Figure 4A), whereas no differences 
existed among groups concerning responses to the endothelium‐independent vasodilator sodium 
nitroprusside (Figure 4B). Collectively, these data suggest that blueberry metabolites normalize a 
palmitate‐induced defect that is specific to the endothelium. These data are congruent with 
reports indicating that blueberry consumption is beneficial concerning blood pressure and 
endothelial function in subjects with metabolic syndrome.11, 17 Taken together results from our 
study suggest that the benefits of blueberry consumption might be mediated through their 
circulating metabolites. 
 
 
Figure 4. Aorta segments were incubated for 16 h with BSA, 500 μM palmitate, or 500 μm palmitate + blueberry 
metabolites. A) Endothelium‐dependent vasorelaxation was determined by evaluating responses to acetylcholine. B) 
Endothelium‐independent vasorelaxation was determined by evaluating responses to sodium nitroprusside. Values 
are mean ± SEM, n = 8 (means of duplicate). Means without a common letter differ, p < 0.05. 
 
4 Concluding Remarks 
 
Blueberry metabolites lessen indices of lipotoxicity‐induced oxidant stress, inflammation, and 
monocyte adhesion in HAECs, and attenuate lipotoxicity‐evoked endothelial dysfunction in 
arteries. A possible explanation for these findings is that blueberry metabolites suppress NOX‐
mediated ROS production, which increases bioavailable NO to an extent that improves 
endothelial cell function (Figure 5). These results indicate that the benefits of blueberry 
consumption in the context of lipotoxicity‐induced vascular dysfunction, at least in part, are 
secondary to their metabolites. Herein we provide solid proof of concept that blueberries might 
prevent, delay the onset, or lessen the severity of lipotoxicity‐induced endothelial dysfunction. 
 
 
Figure 5. Working hypothesis for the protective effect of blueberry metabolites on endothelial cell function. 
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